T. Kobayashi
29 Papers
5 Citations
T. Kobayashi is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 3, co-authored 18 publications.
Chat about Author
Papers
Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.
Geert R. D'Haens,T. Kobayashi,Nathan Morris,Trevor Lissoos,Amy Hoover,X. Li,V Arora,Catherine Milch,W J Sandborn,B.E. Sands +9 more
TL;DR: In this phase 3 UC study, 300mg miri IV demonstrated statistically significant and clinically meaningful improvements vs PBO in all primary and key secondary endpoints across clinical, endoscopic, histologic, and symptomatic measures, with an acceptable safety profile.
DOP24 Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trial
K. Watanabe,Tadanori Hisamatsu,Hiroshi Nakase,Kazuko Nagase,Minoru Matsuura,N. Aoyama,T. Kobayashi,Hirotake Sakuraba,Katsumi Yokoyama,Masakazu Nishishita,Masami Esaki,Fumihito Hirai,Masakazu Nagahori,Sohachi Nanjo,Teppei Omori,Satoshi Tanida,Yoshihiro Yokoyama,Kuniko Moriya,Atsuo Maemoto,O. Handa,N Ohmiya,Shinichiro Shinzaki,Sari Kato,H. Tanaka,T Uraoka,Noritaka Takatsu,H. Suzuki,Kan Takahashi,Junji Umeno,Yoshiyuki Mishima,K. Tsuchida,Mikihiro Fujiya,Sakiko Hiraoka,S. Yamamoto,Masayuki Saruta,Masanori Nojima,Akira Andoh +36 more
TL;DR: Investigation of the immune responses and safety in fully vaccinated Japanese patients with IBD found that GMTs were significantly influenced by increasing age and allergy, and tended to be influenced by COVID-19 infection.
DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab
Remo Panaccione,Christophe Rapin,F. Chan-Diehl,R. Moses,Britta Siegmund,Alissa Walsh,T. Kobayashi,D. Parambir,Simon Travis +8 more
TL;DR: In this article , the relationship between improved histologic and endoscopic endpoints and improvement of the inflammatory biomarkers faecal calprotectin (fCal) and C-reactive protein (CRP) was studied within miri-treated patients enrolled in the programme.
P775 Disease activity and treatment patterns of newly diagnosed adult patients with Crohn's disease in Japan: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD)
S. Shinzaki,Kentaro Matsuoka,Toshimitsu Fujii,Ryoici Okamoto,Akira Yamada,Reiko Kunisaki,Minoru Matsuura,K. Watanabe,Hisashi Shiga,Noritaka Takatsu,Shigeki Bamba,Yohei Mikami,T Yamamoto,Takahiro Shimoyama,Satoshi Motoya,Takahiro Torisu,T. Kobayashi,N Ohmiya,Masayuki Saruta,K. Matsuda,T. Matsumoto,Hideyuki Nakase,Atsuo Maemoto,Yousuke Murata,S. Yoshigoe,H. Tsuchiya,Tadanori Hisamatsu +26 more
TL;DR: The iCREST-CD registry as mentioned in this paper , a prospective, non-interventional, longitudinal, observational registry study conducted at 19 tertiary centers to understand the characteristics of Crohn's disase (CD) treatments in actual clinical settings in Japan, conducted an interim analysis (cutoff date: 30 June 2022) to mainly evaluate the indication and outcomes of initial biologic therapy.
P094 Impacts of 5-aminosalicylic acid on the intestinal microbiota leading to the anti-inflammatory effect
Hirotaka Wada,Jun Miyoshi,Satoshi Kuronuma,Noritaka Hibi,Yuu Nishinarita,N. Oguri,M Matsuura,Osamu Takeuchi,T. Kobayashi,Y. Akimoto,Toshifumi Hibi,Tadanori Hisamatsu +11 more
TL;DR: This paper showed that 5-aminosalicylic acid (5-ASA) is widely used for the treatment of inflammatory bowel disease (IBD), while its anti-inflammatory mechanisms remain controversial.